

Supplementary Material

Operationally simple regioselective 5'-phosphorylation of unprotected 5-ethynyl-2'-deoxyuridine analogues

David H. Hilko,^{A,B} Laurent F. Bornaghi,^A and Sally-Ann Poulsen^{A,B}

^AGriffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, Nathan, Qld 4111, Australia.

^BCorresponding authors. Email: d.hilko@griffith.edu.au; s.poulsen@griffith.edu.au

Table of Contents

Material	Page
Synthetic scheme of dF-EdU (35)	S4
Synthesis of 2'-dideoxy-2'-difluoro-uridine (S1)	S4-S5
Synthesis of 3',5'- <i>O</i> -bis-acetyl-2'-dideoxy-2'-difluoro-uridine (S2)	S5
Synthesis of 3',5'- <i>O</i> -bis-acetyl-2'-dideoxy-2'-difluoro-5-iodo-uridine (S3)	S6
Synthesis of 3',5'- <i>O</i> -bis-acetyl-2'-dideoxy-2'-difluoro-5-(ethynyl(2-trimethylsilyl))-uridine (S4)	S6-S7
2'-dideoxy-2'-difluoro-5-ethynyl-uridine (35)	S7
Synthetic scheme of F-ribo-EdU (34)	S8
Synthesis of (2' <i>R</i>)-3',5'- <i>O</i> -bis-acetyl-2'-deoxy-2'-fluoro-uridine (S6)	S8
Synthesis of (2' <i>R</i>)-3',5'- <i>O</i> -bis-acetyl-2'-deoxy-2'-fluoro-5-iodo-uridine (S7)	S9
Synthesis of (2' <i>R</i>)-3',5'- <i>O</i> -bis-acetyl-2'-deoxy-5-(ethynyl(2-trimethylsilyl))-2'-fluoro-uridine (S8)	S9-S10
Synthesis of (2' <i>R</i>)-2'-deoxy-5-ethynyl-2'-fluoro-uridine (F-ribo-EdU) (34)	S10
References	S10-S11
Compound 2 ¹ H and ¹³ C NMR (DMSO- <i>d</i> ₆)	S12
Compound 2 ³¹ P{H} NMR (DMSO- <i>d</i> ₆)	S13
Compound 4 ¹ H and ¹³ C NMR (DMSO- <i>d</i> ₆)	S14
Compound 4 ³¹ P{H} NMR (DMSO- <i>d</i> ₆)	S15


Compound 5 ^1H and ^{13}C NMR (DMSO- d_6)	S16
Compound 5 $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6).....	S17
Compound 6 ^1H and ^{13}C NMR (DMSO- d_6)	S18
Compound 6 $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6).....	S19
Compound 7 ^1H and ^{13}C NMR (DMSO- d_6)	S20
Compound 7 $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6).....	S21
Compound 8 ^1H and ^{13}C NMR (DMSO- d_6)	S22
Compound 8 $^{19}\text{F}\{\text{H}\}$ and $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)	S23
Compound 9 ^1H and ^{13}C NMR (DMSO- d_6)	S24
Compound 9 $^{19}\text{F}\{\text{H}\}$ and $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)	S25
Compound 10 ^1H and ^{13}C NMR (DMSO- d_6)	S26
Compound 10 $^{19}\text{F}\{\text{H}\}$ and $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)	S27
Compound 11 ^1H and ^{13}C NMR (DMSO- d_6)	S28
Compound 11 $^{19}\text{F}\{\text{H}\}$ and $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)	S29
Compound 12 ^1H and ^{13}C NMR (DMSO- d_6)	S30
Compound 12 $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6).....	S31
Compound 13 ^1H and ^{13}C NMR (DMSO- d_6)	S32
Compound 13 $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6).....	S33
Compound 14 ^1H and ^{13}C NMR (DMSO- d_6)	S34
Compound 14 $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6).....	S35
Compound 15 ^1H and ^{13}C NMR (DMSO- d_6)	S36
Compound 15 $^{19}\text{F}\{\text{H}\}$ and $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)	S37
Compound 20 ^1H and $^{31}\text{P}\{\text{H}\}$ NMR (CDCl_3)	S38
Compound 24 ^1H and ^{13}C NMR (CDCl_3).....	S39
Compound 24 $^{31}\text{P}\{\text{H}\}$ NMR (CDCl_3)	S40
Compound 25 ^1H and ^{13}C NMR (CDCl_3).....	S41
Compound 25 $^{31}\text{P}\{\text{H}\}$ NMR (CDCl_3)	S42
Compound 26 ^1H and ^{13}C NMR (CDCl_3).....	S43
Compound 26 $^{31}\text{P}\{\text{H}\}$ NMR (CDCl_3)	S44
Compound S1 ^1H NMR MeOD- d_4) and ^{13}C NMR (DMSO- d_6).....	S45
Compound S1 ^{19}F NMR (MeOD- d_4).....	S46
Compound S2 ^1H and ^{13}C NMR (CDCl_3)	S47
Compound S2 $^{19}\text{F}\{\text{H}\}$ NMR (CDCl_3)	S48
Compound S3 ^1H and ^{13}C NMR (CDCl_3)	S49

Compound S3 $^{19}\text{F}\{\text{H}\}$ NMR (CDCl_3)	S50
Compound S4 ^1H and ^{13}C NMR (CDCl_3)	S51
Compound S4 $^{19}\text{F}\{\text{H}\}$ NMR (CDCl_3)	S52
Compound S4 ^1H and $^{19}\text{F}\{\text{H}\}$ NMR ($\text{DMSO-}d_6$)	S53
Compound S6 ^1H and $^{19}\text{F}\{\text{H}\}$ NMR (CDCl_3)	S54
Compound S7 ^1H and ^{13}C NMR (CDCl_3)	S55
Compound S7 $^{19}\text{F}\{\text{H}\}$ NMR (CDCl_3)	S56
Compound S8 ^1H and ^{13}C NMR (CDCl_3)	S57
Compound S8 $^{19}\text{F}\{\text{H}\}$ NMR (CDCl_3)	S58
Compound S5 ^1H and ^{13}C NMR ($\text{DMSO-}d_6$)	S59
Compound S5 $^{19}\text{F}\{\text{H}\}$ NMR ($\text{DMSO-}d_6$)	S60
Stacked spectra of Compound 2 $^{31}\text{P}\{\text{H}\}$ NMR and $^{31}\text{P}\{\text{H}\}$ NMR Crude reaction mixture for synthesis of compound 2 ($\text{pyridine-}d_5$)	S61

1 Fluorinated nucleosides **34** and **35** are novel and their synthesis is reported below. To the
2 best of our knowledge, intermediate compounds **S3**, **S4** and **S8** are novel while
3 spectroscopic data for **24** has not been reported previously.

4 We found that deamination of commercially available gemcitabine employing
5 diazotisation conditions proceeded efficiently at 0 °C to afford 2'-dideoxy-2'-difluoro-
6 uridine (157) in 98% yield (**Scheme S1**). Compound **S1** was subsequently acetylated with
7 Ac₂O, employing pyridine as base and solvent, to give the 3',5'-protected intermediate
8 **S2** in quantitative yield. The synthesis then follows the synthetic strategies previously
9 developed for the synthesis of EdU. This involves iodination of the 5 position of **S2** to
10 give **S3**, followed by Sonogashira coupling with ethynyl-2-trimethylsilane to give **S4**, and
11 lastly deprotection to afford dF-EdU (**35**) in 67% yield.

12



13

14 **Scheme S1**. Synthesis of dF-EdU (**35**) from gemcitabine.

15

16 2'-Dideoxy-2'-difluoro-uridine (**S1**)

17 Gemcitabine (1.00 g, 3.093 mmol) was dissolved in H₂O (1.8 mL) and AcOH (3.5 mL)
18 and cooled to 0 °C. NaNO₂ dissolved in a minimum amount of H₂O was slowly added to
19 the reaction mixture with stirring. The mixture was stirred for 3 h at 0 °C at which point
20 TLC analysis indicated complete conversion of starting material to a single product. The
21 mixture was allowed to warm to rt and was then poured into acetone (100 mL). The

precipitated salts were filtered off and the solvent removed *in vacuo*. The residue was co-
evaporated with EtOH (2×) then the residue dissolved in MeOH and adsorbed onto silica
gel. The crude product was purified by silica gel flash chromatography to afford the title
compound as a clear oil (quantitative). Spectroscopic data was consistent with literature
values.¹ $R_f = 0.23$ (10% MeOH in CH_2Cl_2). $^1\text{H NMR}$ (500 MHz, $\text{MeOD-}d_4$) $\delta_{\text{H}} = 7.87$ (d,
 $J = 8.2$ Hz, 1H), 6.17 – 6.12 (m, 1H), 5.73 (d, $J = 8.2$ Hz, 1H), 4.28 (td, $J = 12.1, 8.1$ Hz,
1H), 3.96 – 3.87 (m, 2H), 3.78 (dd, $J = 12.5, 3.1$ Hz, 1H). $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$)
 $\delta_{\text{H}} = 11.57$ (br s, 1H, NH), 7.79 (d, $J = 8.2$ Hz, 1H, H-6'), 6.06 (t, $J = 7.9$ Hz, 1H, H-1'),
5.72 (d, $J = 8.1$ Hz, 1H, H-5), 4.18 (td, $J = 12.8, 8.4$ Hz, 1H, H-3'), 3.83 (ddd, $J = 8.4,$
3.6, 2.5 Hz, 1H, H-4'), 3.76 (dd, $J = 12.7, 2.4$ Hz, 1H, H-5'(α or β)), 3.62 (dd, $J = 12.7, 3.6$
Hz, 1H, H-5'(α or β)). $^{19}\text{F NMR}$ (470 MHz, $\text{MeOD-}d_4$) $\delta = -118.6$ (dd, $J = 13.2, 4.8$ Hz), -
119.2 (dd, $J = 13.3, 5.0$ Hz), -120.0, -120.5. LRMS (ESI): $m/z = 265$ [$\text{M} + \text{H}$]⁺, 263 [$\text{M} -$
H]⁻, 309 [$\text{M} + \text{HCO}_2$]⁻.

35

36 3',5'-*O*-Bis-acetyl-2'-dideoxy-2'-difluoro-uridine (**S2**)

Compound **S1** was dissolved in pyridine (3.3 mL, 30.93 mmol, 10 equiv) and Ac_2O (0.73
mL, 7.73 mmol, 2.5 equiv) and the mixture stirred at rt for 8 h. EtOAc (50 mL) was added
and the organic material washed with 5% $\text{HCl}_{(\text{aq})}$ (20 mL), $\text{NaHCO}_{3(\text{satd. aq})}$ (20 mL), brine
(20 mL) and dried over MgSO_4 . The solvent was removed to give the title compound as
a yellow gum (quantitative). $R_f = 0.16$ (30% EtOAc in CH_2Cl_2). $^1\text{H NMR}$ (500 MHz,
 CDCl_3) $\delta_{\text{H}} = 9.40$ (br s, 1H, NH), 7.36 (dd, $J = 8.2, 2.4$ Hz, 1H, H-6), 6.26 (dd, $J = 11.9,$
6.3 Hz, 1H, H-1'), 5.81 (d, $J = 8.2$ Hz, 1H, H-5), 5.25 (ddd, $J = 13.8, 5.5, 3.0$ Hz, 1H, H-
3'), 4.39 (d, $J = 4.2$ Hz, 2H, H-5'(α and β)), 4.29 (q, $J = 4.4$ Hz, 1H, H-4'), 2.20 (s, 3H, Ac),
2.12 (s, 3H, Ac). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta_{\text{C}} = 170.4$ (H_3CCO_2), 169.1 (H_3CCO_2),
162.6 (C-4), 150.2 (C-2), 139.8 (d, $J = 3.7$ Hz, C-6), 120.5 (dd, $J = 266.4, 259.1$ Hz, C-
2'), 103.4 (C-5), 83.1 (dd, $J = 38.0, 20.8$ Hz, C-1'), 78.0 (dd, $J = 4.6, 2.5$ Hz, C-4'), 70.7
(dd, $J = 34.2, 17.0$ Hz, C-3'), 62.1 (C-5'), 20.8 (H_3CCO_2), 20.5 (H_3CCO_2). $^{19}\text{F NMR}$ (470
MHz, CDCl_3) $\delta_{\text{F}} = -116.8$ (dt, $J = 247.4, 12.3$ Hz), -121.4 (d, $J = 250.4$ Hz). LRMS (ESI):
 $m/z = 349$ [$\text{M} + \text{H}$]⁺, 347 [$\text{M} - \text{H}$]⁻. HRMS (ESI⁺) m/z [$\text{M} + \text{Na}$]⁺ calcd. for
 $\text{C}_{13}\text{H}_{14}\text{F}_2\text{N}_2\text{NaO}_7$ 371.0661, found 371.0634.

52

53 3',5'-*O*-Bis-acetyl-2'-dideoxy-2'-difluoro-5-iodo-uridine (**S3**)

54 Compound **S3** was synthesised from compound **S2** (0.980 g, 2.815 mmol) according to
55 adapted literature procedures.² The crude product was purified by silica gel flash
56 chromatography (5 – 20% EtOAc in CH₂Cl₂) to afford the title compound as a pale yellow
57 foam/gum (1.20 g, 90%). *R_f* = 0.52 (30% EtOAc in CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃)
58 δ_H = 8.90 (br s, 1H, NH), 7.80 (d, *J* = 2.2 Hz, 1H, H-6), 6.24 (dd, *J* = 10.5, 6.9 Hz, 1H,
59 H-1'), 5.29 (ddd, *J* = 13.3, 5.7, 3.9 Hz, 1H, H-3'), 4.42 (d, *J* = 3.5 Hz, 2H, H-5'(_α and _β)),
60 4.35 – 4.29 (m, 1H, H-4'), 2.21 (2× s, 6H, Ac). ¹³C NMR (126 MHz, CDCl₃) δ_C = 170.4
61 (H₃CCO₂), 169.1 (H₃CCO₂), 159.3 (C-4), 149.5 (C-2), 144.1 (H-6), 120.6 (dd, *J* = 265.7,
62 260.0 Hz, C-2'), 83.4 (dd, *J* = 38.2, 20.7 Hz, C-1'), 78.3 (d, *J* = 2.1 Hz, H-4'), 70.5 (dd, *J*
63 = 33.8, 17.0 Hz, H-3'), 69.4 (C-5), 61.9 (C-5'), 21.0 (H₃CCO₂), 20.5 (H₃CCO₂). ¹⁹F NMR
64 (470 MHz, CDCl₃) δ_F = -116.3 (dt, *J* = 247.9, 11.8 Hz), -120.6 (d, *J* = 247.7 Hz). LRMS
65 (ESI): *m/z* = 475 [M + H]⁺, 473 [M - H]⁻. HRMS (ESI⁺) *m/z* [M + Na]⁺ calcd. for
66 C₁₃H₁₃F₂IN₂NaO₇ 496.9628, found 496.9590.

67

68 3',5'-*O*-Bis-acetyl-2'-dideoxy-2'-difluoro-5-(ethynyl(2-trimethylsilyl))-uridine (**S4**)


69 Compound **S4** was synthesised from compound **S3** (1.400 g, 2.953 mmol) using
70 Sonagashira conditions. **S3** was combined with CuI (0.056 g, 0.295 mmol, 0.1 equiv),
71 Pd(PPh₃)₄ (0.154 g, 0.148 mmol, 0.05 equiv) under an atmosphere of argon. The mixture
72 was suspended in anhydrous CH₂Cl₂ (10 mL) and ethynyl-2-trimethylsilane (2 ml, 14.7
73 mmol, 5 equiv) added immediately, followed by Et₃N (0.8 mL, 5.9 mmol, 2 equiv). Upon
74 addition of Et₃N the reaction mixture clarified and developed a yellow-orange colour. The
75 mixture was stirred at rt until complete consumption of **S3** was evident by TLC (2 – 3 h).
76 The solvent was removed *in vacuo* and the residue dissolved in EtOAc. The EtOAc
77 fraction was washed with 5% HCl_(aq) (20 mL), NaHCO_{3(satd. aq)} (20 mL), 1.0 M EDTA-Na
78 (3 × 20 mL) and brine (20 mL) then dried over MgSO₄ and concentrated *in vacuo*. The
79 crude product was purified by silica gel flash chromatography (10 – 20% EtOAc in
80 CH₂Cl₂) to afford the title compound as a colourless foam (1.246 g, 95 %). *R_f* = 0.66 (30%
81 EtOAc in CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ_H = 8.98 (br s, 1H, NH), 7.66 (d, *J* =
82 2.0 Hz, 1H, H-6), 6.26 (t, *J* = 8.4 Hz, 1H, H-1'), 5.31 (dt, *J* = 12.9, 5.8 Hz, 1H, H-3'), 4.44
83 (dd, *J* = 12.7, 3.1 Hz, 1H, H-5'(_α or _β)), 4.38 (dd, *J* = 12.7, 3.5 Hz, 1H, H-5'(_α or _β)), 4.31 (dt,
84 *J* = 6.4, 3.3 Hz, 1H, H-4'), 2.20 (s, 3H, Ac), 2.18 (s, 3H, Ac), 0.22 (s, 9H, Si(CH₃)₃). ¹³C

85 NMR (126 MHz, CDCl₃) δ_C = 170.2 (H₃CCO₂), 169.1 (H₃CCO₂), 160.3, 148.9 (C-2),
86 142.4 (d, J = 2.7 Hz, C-6), 120.6 (dd, J = 264.4, 261.3 Hz, C-2'), 101.5 (C-5), 100.6
87 (C \equiv C), 94.6 (C \equiv C), 83.7 (dd, J = 39.5, 21.6 Hz, C-1'), 78.0 (d, J = 5.6 Hz, C-4'), 70.3 (dd,
88 J = 32.9, 17.0 Hz, C-3') 61.8 (C-5'), 20.9 (H₃CCO₂), 20.5 (H₃CCO₂), -0.1 (Si(CH₃)₃). ¹⁹F
89 NMR (470 MHz, CDCl₃) δ_F = -115.9 (dt, J = 247.6, 10.8 Hz), -119.6 (d, J = 249.6 Hz).
90 LRMS (ESI): m/z = 445 [M + H]⁺, 443 [M - H]⁻. HRMS (ESI⁺) m/z [M + Na]⁺ calcd. for
91 C₁₈H₂₂F₂N₂NaO₇Si 467.1057, found 467.1018.

92

93 2'-dideoxy-2'-difluoro-5-ethynyl-uridine (**35**)

94 Compound **S4** (0.466 g, 1.049 mmol) was dissolved in MeOH (15 mL) and sodium
95 methoxide (4.6 M) (0.187 mL, 0.0404 mmol) added. The mixture was stirred at rt for 3
96 hours after which TLC analysis indicated complete consumption of the starting material
97 and formation of a single product. The mixture was neutralised with Amberlite IRA-120
98 H⁺ resin and filtered. The crude compound was adsorbed onto silica and purified by solid
99 addition silica gel flash chromatography (10 % MeOH in CH₂Cl₂) to afford the title
100 compound as a pale yellow solid (0.257 g, 85%). Spectroscopic data was consistent with
101 literature.¹ R_f = 0.11 (5% MeOH in CH₂Cl₂). Darkens at 190-205 °C, mp = 210-215 °C.
102 ¹H NMR (500 MHz, DMSO) δ_H = 11.91 (br s, 1H, NH), 8.26 (s, 1H, H-6), 6.32 (d, J =
103 6.6 Hz, 1H, OH-3'), 6.04 (t, J = 7.3 Hz, 1H, H-1'), 5.42 (t, J = 5.2 Hz, 1H, OH-5'), 4.22
104 (tdd, J = 12.4, 10.6, 8.3, 5.6 Hz, 1H, H-3'), 4.17 (s, 1H), 3.86 (dt, J = 8.6, 2.7 Hz, 1H, H-
105 4'), 3.79 (dt, J = 12.8, 3.0 Hz, 1H, H-5'(α or β)), 3.64 (ddd, J = 12.7, 5.4, 3.1 Hz, 1H, H-5'(α
106 or β)). ¹⁹F NMR (470 MHz, DMSO) δ_F = -116.3, -116.5 (d, J = 12.3 Hz), -116.83 (d, J =
107 13.5 Hz), -117.00 (d, J = 13.1 Hz), -117.18, -117.70. LRMS (ESI): m/z = 289 [M + H]⁺,
108 287 [M - H]⁻.



109

110

111 **Scheme S2.** Synthesis of 2'-F-ribo-EdU (**34**) from commercially available 2'-deoxy-2'-fluoro-
 112 deoxyuridine (**S5**) employing an adapted procedure for the synthesis of EdU.

113

114 (2'*R*)-3',5'-*O*-Bis-acetyl-2'-deoxy-2'-fluoro-uridine (**S6**)

115 Compound **S6** was synthesised from commercially available (2'*R*)-2'-deoxy-2'-fluoro-
 116 uridine (**S5**) (2.000 g, 8.127 mmol). Compound **S5** was dissolved in pyridine (8.8 mL,
 117 81.0 mmol, 10 equiv) then Ac₂O (1.92 mL, 20.3 mmol, 2.5 mmol) was added and mixture
 118 stirred for at rt 16 h. The reaction mixture was dissolved in EtOAc (50 mL) and washed
 119 with 5% HCl_(aq) (20 mL), NaHCO_{3(satd. aq)} (20 mL), brine (20 mL) and dried over MgSO₄
 120 to give the title compound as a yellow gum (2.623 g, 98%). The spectroscopic data was
 121 consistent with literature values.²⁻³ *R*_f = 0.21 (30% EtOAc in CH₂Cl₂). ¹H NMR (500
 122 MHz, DMSO-*d*₆) δ_H = 11.47 (s, 1H, NH), 7.72 (d, *J* = 8.1 Hz, 1H, H-6), 5.87 (dd, *J* =
 123 22.4, 2.1 Hz, 1H, H-1'), 5.68 (d, *J* = 8.0 Hz, 1H, H-5), 5.53 (ddd, *J* = 52.6, 5.3, 2.1 Hz,
 124 1H, H-2'), 5.26 (ddd, *J* = 17.2, 7.9, 5.3 Hz, 1H, H-3'), 4.34 (dd, *J* = 12.1, 2.9 Hz, 1H, H-
 125 5'_(α or β)), 4.27 (ddd, *J* = 8.2, 5.7, 2.9 Hz, 1H, H-4'), 4.16 (dd, *J* = 12.1, 5.7 Hz, 1H, H-5'_{(α}
 126 or β)), 2.11 (s, 3H, Ac), 2.04 (s, 3H, Ac). ¹H NMR (500 MHz, CDCl₃) δ_H = 9.30 (br s, 1H),
 127 7.39 (d, *J* = 8.1 Hz, 1H), 5.83 – 5.74 (m, 2H), 5.37 (ddd, *J* = 52.2, 4.9, 1.7 Hz, 1H), 5.15
 128 (ddd, *J* = 17.8, 8.3, 5.0 Hz, 1H), 4.44 (dd, *J* = 12.3, 2.6 Hz, 1H), 4.40 (ddd, *J* = 7.6, 4.5,
 129 2.6 Hz, 1H), 4.30 (dd, *J* = 12.3, 4.6 Hz, 1H), 2.15 (s, 3H), 2.11 (s, 3H). ¹³C NMR (126
 130 MHz, DMSO) δ 170.1, 169.5, 150.6, 142.5, 102.1, 90.8 (d, *J* = 187.0 Hz), 90.5 (d, *J* =

131 36.4 Hz), 77.9, 69.8 (d, $J = 14.8$ Hz), 62.67, 20.5, 20.3. ^{19}F NMR (470 MHz, CDCl_3) δ -
132 198.76 – -199.06 (m). LRMS (ESI): $m/z = 353$ $[\text{M} + \text{Na}]^+$, 331 $[\text{M} + \text{H}]^+$, 329 $[\text{M} - \text{H}]^-$.

133

134 (2'*R*)-3',5'-*O*-Bis-acetyl-2'-deoxy-2'-fluoro-5-iodo-uridine (**S7**)

135 Compound **S7** was synthesised from compound **S6** (2.68 g, 8.11 mmol) according to
136 literature procedures.² Briefly, compound **S6**, ceric ammonium nitrate (4.45 g, 8.11
137 mmol, 1 equiv), and I_2 (1.64 g, 6.49 mmol 0.8 equiv) were combined and dissolved in
138 CH_3CN (40 mL) and heated to 50 °C for 16 h. The solvent was then removed *in vacuo*
139 and the residue dissolved in EtOAc (20 mL) and washed with NaHCO_3 (satd. aq.) (20 mL)
140 and brine (20 mL) then dried over MgSO_4 . The crude product was purified by silica gel
141 flash chromatography (10 – 30% EtOAc in CH_2Cl_2) to afford the title compound as a pale
142 red solid (3.330 g, 90%). $R_f = 0.52$ (30% EtOAc in CH_2Cl_2). mp 135-140 °C. The
143 spectroscopic data was consistent with literature values.³ ^1H NMR (500 MHz, CDCl_3) δ
144 8.97 (s, 1H, NH), 7.89 (s, 1H, H-6), 5.89 (dd, $J = 18.2, 1.7$ Hz, 1H, H-1'), 5.30 (ddd, $J =$
145 51.7, 4.7, 1.7 Hz, 1H, H-2'), 5.10 (ddd, $J = 18.1, 8.0, 4.8$ Hz, 1H, H-3'), 4.49 – 4.41 (m,
146 2H, H-5'(α or β) and H-4'), 4.36 (dd, $J = 13.2, 4.0$ Hz, 1H, H-5'(α or β)), 2.22 (s, 3H, Ac), 2.16
147 (s, 3H, Ac). ^{13}C NMR (126 MHz, CDCl_3) $\delta_{\text{C}} = 170.5$ (H_3CCO_2), 170.0 (H_3CCO_2), 160.0
148 (C-4), 149.6 (C-2), 144.5 (C-6), 91.1 (d, $J = 193.0$ Hz, C-2'), 90.3 (d, $J = 35.6$ Hz, C-1'),
149 78.9 (C-4'), 69.3 (d, $J = 15.6$ Hz, C-3'), 61.9 (C-5'), 21.3 (H_3CCO_2), 20.5 (H_3CCO_2). ^{19}F
150 NMR (470 MHz, CDCl_3) δ -200.2 (dt, $J = 51.9, 18.2$ Hz). LRMS (ESI): $m/z = 457$ $[\text{M} +$
151 $\text{H}]^+$, 455 $[\text{M} - \text{H}]^-$.

152

153 (2'*R*)-3',5'-*O*-Bis-acetyl-2'-deoxy-5-(ethynyl(2-trimethylsilyl))-2'-fluoro-uridine (**S8**)

154 Compound **S8** was synthesised from compound **S7** (1.700 g, 3.728 mmol) under
155 Sonagashira conditions, similarly to **S4** described above. The crude product was purified
156 by silica gel flash chromatography (10 – 20% EtOAc in CH_2Cl_2) to afford the title
157 compound as an off-white solid (0.921 g, 58%). mp 195-198 °C. $R_f = 0.69$ (30% EtOAc
158 in CH_2Cl_2). ^1H NMR (500 MHz, CDCl_3) $\delta_{\text{H}} = 8.74$ (s, 1H, NH), 7.79 (s, 1H, H-6), 5.95
159 (dd, $J = 17.6, 1.5$ Hz, 1H, H-1'), 5.26 (ddd, $J = 51.6, 4.7, 1.5$ Hz, 1H, H-2'), 5.07 (ddd, J
160 = 18.9, 8.4, 4.7 Hz, 1H, H-3'), 4.49 – 4.43 (m, 2H, H-5'(α or β) and H-4'), 4.38 – 4.31 (m,
161 1H, H-5'(α or β)), 2.19 (s, 3H, Ac), 2.16 (s, 3H, Ac), 0.21 (s, 9H, $\text{Si}(\text{CH}_3)_3$). ^{13}C NMR (126

162 MHz, CDCl₃) δ_C = 170.2 (H₃CCO₂), 170.0 (H₃CCO₂), 160.6 (C-4), 148.7 (C-2), 142.5
163 (C-6), 101.1 (C \equiv C-Si), 100.6 (C-5), 94.8 (C \equiv C-Si), 91.2 (d, J = 193.4 Hz, C-2'), 89.9 (d,
164 J = 35.3 Hz, C-1'), 78.8, 69.1 (d, J = 15.7 Hz, C-3'), 61.6 (C-5'), 21.1 (H₃CCO₂), 20.5
165 (H₃CCO₂), -0.1 (Si(CH₃)₃). ¹⁹F NMR (470 MHz, CDCl₃) δ_F = -201.4 (dt, J = 51.8, 18.2
166 Hz). LRMS (ESI): m/z = 427 [M + H]⁺, 425 [M - H]⁻. HRMS (ESI⁺) m/z [M + Na]⁺ calcd.
167 for C₁₈H₂₃FN₂NaO₇Si 449.1151, found 449.1122.

168

169 (2'*R*)-2'-Deoxy-5-ethynyl-2'-fluoro-uridine (**34**)

170 Compound **S8** (0.880 g, 1.049 mmol) was dissolved in MeOH (30 mL) and sodium
171 methoxide (4.6 M) (0.368 mL, 1.70 mmol) added. The mixture was stirred at rt for 2 h
172 after which TLC analysis indicated complete consumption of the starting material and
173 formation of a single product. The mixture was neutralised with Amberlite IRA-120 H⁺
174 resin and filtered. Silica gel was added to the filtrate and the solvent removed *in vacuo*.
175 The compound was purified by solid addition silica gel flash chromatography (10%
176 MeOH in CH₂Cl₂) to afford the title compound as an off-white foam (0.280 g, 50%). R_f
177 = 0.27 (10% MeOH in CH₂Cl₂). ¹H NMR (500 MHz, DMSO-*d*₆) δ_H = 11.69 (br s, 1H,
178 NH), 8.41 (s, 1H, H-6), 5.86 (dd, J = 16.9, 1.3 Hz, 1H, H-1'), 5.60 (d, J = 6.6 Hz, 1H,
179 OH-3'), 5.36 (t, J = 4.7 Hz, 1H, OH-5'), 5.03 (ddd, J = 53.1, 4.3, 1.4 Hz, 1H, H-1'), 4.24
180 – 4.11 (m, 1H, H-3'), 4.08 (s, 1H, \equiv C-H), 3.89 (dt, J = 8.3, 2.5 Hz, 1H, H-4'), 3.81 (ddd,
181 J = 12.4, 4.4, 2.3 Hz, 1H, H-5'(α or β)), 3.60 (ddd, J = 12.3, 4.4, 2.5 Hz, 1H, H-5'(α or β)). ¹³C
182 NMR (126 MHz, DMSO-*d*₆) δ_C = 162.0 (C-4), 149.5 (C-2), 144.5 (C-6), 97.6 (C-5), 93.9
183 (d, J = 185.3 Hz, C-2'), 87.7 (d, J = 34.2 Hz, C-1'), 83.7 (C \equiv C-H), 83.2 (C-4'), 76.5 (C \equiv C-
184 H), 66.9 (d, J = 16.3 Hz, C-3'), 58.7 (C-5'). ¹⁹F NMR (470 MHz, DMSO-*d*₆) δ_F = -202.5
185 (ddd, J = 53.0, 23.5, 16.8 Hz). LRMS (ESI): m/z = 293 [M + Na]⁺, 271 [M + H]⁺, 269 [M
186 - H]⁻. HRMS (ESI⁺) m/z [M + Na]⁺ calcd. for C₁₁H₁₁FN₂NaO₅ 293.0544, found 293.0542.

187


188 References

- 189 1. Neef, A. B.; Pernot, L.; Schreier, V. N.; Scapozza, L.; Luedtke, N. W., A Bioorthogonal
190 Chemical Reporter of Viral Infection. *Angew. Chem.* **2015**, *127* (27), 8022-8025.
191 2. Brunner, K.; Harder, J.; Halbach, T.; Willibald, J.; Spada, F.; Gnerlich, F.; Sparrer, K.;
192 Beil, A.; Möckl, L.; Bräuchle, C.; Conzelmann, K.-K.; Carell, T., Cell-Penetrating and
193 Neurotargeting Dendritic siRNA Nanostructures. *Angew. Chem. Int. Ed.* **2015**, *54* (6), 1946-
194 1949.


195 3. Kniess, T.; Grote, M.; Noll, B.; Johannsen, B., Synthesis and Enzymatic Evaluation of
196 Nucleosides Derived from 5-Iodo-2'-Halo-2'-Deoxyuridines. In *Zeitschrift für Naturforschung*
197 *B*, 2003; Vol. 58, p 226.

198


Compound **2** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **2** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **4** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **4** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **5** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **5** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **6** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **6** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **7** ^1H and ^{13}C NMR (DMSO- d_6)




$\text{C}_{18}\text{H}_{15}\text{F}_2\text{N}_2\text{O}_8\text{P}$





Compound **7** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **7** $^{19}\text{F}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **8** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **8** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)





Compound **8** $^{19}\text{F}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **9** ^1H and ^{13}C NMR (DMSO- d_6)




$\text{C}_{19}\text{H}_{17}\text{F}_2\text{N}_2\text{O}_9\text{P}$






Compound **9** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **9** $^{19}\text{F}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **10** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **10** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **10** $^{19}\text{F}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **11** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **11** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **11** $^{19}\text{F}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **12** ^1H and ^{13}C NMR (DMSO- d_6)





Compound **12** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **13** ^1H and ^{13}C NMR (DMSO- d_6)





$\text{C}_{18}\text{H}_{16}\text{ClN}_2\text{O}_8\text{P}$




Compound **13** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)






Compound **14** ^1H and ^{13}C NMR (DMSO- d_6)




Compound **14** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **15** ^1H and ^{13}C NMR (DMSO- d_6)





Compound **15** $^{31}\text{P}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **115** $^{19}\text{F}\{\text{H}\}$ NMR (DMSO- d_6)




Compound **20** ^1H and ^{31}P NMR (CDCl_3)




Compound **24** ^1H and ^{13}C NMR (CDCl_3)





$\text{C}_{14}\text{H}_{22}\text{NO}_2\text{P}$




Compound **24** ^{31}P NMR (CDCl_3)





Compound **25** ^1H and ^{13}C NMR (CDCl_3)




Compound **25** ^{31}P NMR (CDCl_3)





Compound **26** ^1H and ^{13}C NMR (CDCl_3)




Compound **26** ^{31}P NMR (CDCl_3)





Compound **S1** ^1H (MeOD- d_4) and ^{13}C NMR (DMSO- d_6)




Compound **S1** $^{19}\text{F}\{\text{H}\}$ NMR (MeOD- d_4)




Compound **S2** ^1H and ^{13}C NMR (CDCl_3)




Compound **S2** ^{19}F NMR (CDCl_3)




Compound S3 ^1H and ^{13}C NMR (CDCl_3)




Compound **S3** ^{19}F NMR (CDCl_3)






Compound **S4** ^1H and ^{13}C NMR (CDCl_3)





Compound **S4** ^{19}F NMR (CDCl_3)






Compound **34** ^1H and ^{19}F NMR (DMSO- d_6)




Compound **S6** ^1H and ^{19}F NMR (CDCl_3)




Compound **S7** ^1H and ^{13}C NMR (CDCl_3)




Compound **S7** ^{19}F NMR (CDCl_3)





Compound **S8** ^1H and ^{13}C NMR (CDCl_3)




Compound **S8** ^{19}F NMR (CDCl_3)




Compound **35** ^1H and ^{13}C NMR (DMSO- d_6)



Compound **35** ^{19}F NMR ($\text{DMSO-}d_6$)



Compound **2** $^{31}\text{P}\{\text{H}\}$ NMR ($\text{pyridine-}d_5$)



Crude reaction mixture for synthesis of **2** $^{31}\text{P}\{\text{H}\}$ NMR ($\text{pyridine-}d_5$)

